17 completed, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 21 Phase 1, 5 Phase 2, 2 Phase 3.
Follow aluminum sulfate: new trials by email Literature Review of aluminum sulfate trials Research Report on aluminum sulfate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected 426c.Mod.Core-C4b, 3M-052-AF, Aluminum hydroxide suspension (Alum) - HIV Infections | Phase 1 | Not yet recruiting | HIV Vaccine Trials Network | 22 | 2027-03-30 | 2026-09-18 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV 3M-052-AF + Alum, UVAX-1107, UVAX-1197 - HIV-1-infection | Phase 1 | Suspended | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2025-07-07 | 2025-09-04 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health 426c.Mod.Core-C4b, HxB2.WT.Core-C4b, 3M-052-AF adjuvant - HIV | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 42 | 2025-03-17 | 2025-09-25 |
| A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702) - HIV | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-10-07 | 2025-03-26 | |
| A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage - Hiv | Phase 1 | Unknown | International AIDS Vaccine Initiative | 8 | 2024-04-16 | 2024-06-11 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV V3G CH848 Pr-NP1 60mcg, 3M-052-AF 5mcg, Alum 500 mcg - Hiv | Phase 1 | Active not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 36 | 2023-08-29 | 2026-04-20 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) - Hiv | Phase 1 | Unknown | International AIDS Vaccine Initiative | 14 | 2023-06-01 | 2023-05-18 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV sD-NP-GT8 DNA, IL-12 DNA, Trimer 4571 - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 46 | 2023-04-10 | 2025-11-14 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV INO-6160, 2 mg, Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg) - HIV-1-infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2023-04-05 | 2025-09-02 |
| ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine Gamma Variant RBD-based ARVAC-CG vaccine, Omicron Variant RBD-based ARVAC-CG vaccine, Bivalent RBD-based ARVAC-CG vaccine - COVID-19 Vaccine | Phase 2 / Phase 3 | Completed | Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | 2014 | 2023-02-06 | 2023-12-22 |
| Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19) GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1, Normal saline (0.9% sodium chloride solution) - Stage 1, GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1 - COVID-19 (Healthy Volunteers) | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 260 | 2021-01-20 | 2023-04-18 |
| Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19) NBP2001 adjuvanted with alum (RBD 30μg/dose), NBP2001 adjuvanted with alum (RBD 50μg/dose), Normal Saline - COVID-19 (Healthy Volunteers) | Phase 1 | Completed | SK Bioscience Co., Ltd. | 50 | 2020-12-17 | 2023-04-18 |
| Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults BG505 SOSIP.664 gp140, Placebo, 3M-052-AF - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 127 | 2020-01-13 | 2025-09-02 |
| VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults VRC-WEVVLP073-00-VP, VRC-GENMIX083-AL-VP - Venezuelan Equine Encephalitis, Western Equine Encephalitis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2019-04-02 | 2021-03-24 |
| Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults VRC-HIVRGP096-00-VP, Alum Adjuvant - Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV) | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 16 | 2019-03-07 | 2021-08-12 |
| Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults VRC-RSVRGP084-00-VP, Aluminum Hydroxide Suspension - Respiratory Syncytial Virus | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 95 | 2017-02-22 | 2020-10-23 |
| Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis VLA15 with Alum, VLA15 without Alum - Lyme Borreliosis, Nervous System | Phase 1 | Completed | Pfizer | 179 | 2017-01-31 | 2023-04-05 |
| A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease CAD106 Immunotherapy, Placebo to CAD106, CNP520 - Alzheimers Disease | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 480 | 2015-11-30 | 2021-07-08 |
| Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea Capsule-Conjugate Campylobacter Vaccine (CJCV1), Alhydrogel®, aluminum hydroxide adjuvant (alum) - Campylobacter Infection | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 48 | 2014-04-21 | 2018-02-23 |
| Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine HBsAg, PreS HBsAg, Advax-1(TM) - Exposure to Hepatitis B Virus | Phase 1 | Completed | Vaxine Pty Ltd | 240 | 2013-07-01 | 2019-05-07 |
Showing 20 of 25. Sign in to see all of them.
Acquired Immunodeficiency Syndrome (4) · HIV Infections (4) · Alzheimer Disease (3) · COVID-19 (2) · Alphavirus Infections (1) · Campylobacter Infections (1) · Central Nervous System Diseases (1) · Encephalomyelitis, Eastern Equine (1) · Encephalomyelitis, Venezuelan Equine (1) · Encephalomyelitis, Western Equine (1) · Hepatitis B (1) · Influenza, Human (1) · Lyme Disease (1) · Lyme Neuroborreliosis (1) · Neurodegenerative Diseases (1)
National Institute of Allergy and Infectious Diseases (NIAID) (10) · International AIDS Vaccine Initiative (2) · Novartis Pharmaceuticals (2) · SK Bioscience Co., Ltd. (2) · Affiris AG (1) · Alexey Mukhin (1) · Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno (1) · HIV Vaccine Trials Network (1) · PX'Therapeutics (1) · Pfizer (1) · U.S. Army Medical Research and Development Command (1) · University Hospitals, Leicester (1) · Vaxine Pty Ltd (1)
United States (15) · Belgium (3) · Netherlands (3) · South Africa (3) · United Kingdom (3) · Australia (2) · Canada (2) · Germany (2) · South Korea (2) · Spain (2) · Switzerland (2) · Argentina (1) · Austria (1) · Finland (1) · Italy (1)
Alexey G Mukhin, M.D., Ph.D. (1) · Amy Violari (1) · Godelieve de Bree (1) · Grace Chen, MD (1) · Grace L Chen, M.D. (1) · Gustavo Yerino, MD (1) · Hee Jin Cheong (1) · Jeffrey Barbara, MBBS PhD (1) · Julie E Ledgerwood, DO (1) · Karl G Nicholson, FRCP, MD (1) · M. Juliana McElrath (1) · Margaret Johnson, Pr (1) · Martin R Gaudinski, M.D. (1) · Myoung-Don Oh (1)
PMID 33864736, PMID 33873199, PMID 35568049, PMID 35783486, PMID 36542692, PMID 37419129, PMID 40179522
1UF1AG046150-01 (1), 2009 (1), 2015 (1), UM1AI068614 (1)